A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)
Recruiting now · Phase 1/Phase 2
Conditions studied: Primary Photoreceptor Disease, Retinitis Pigmentosa (RP), Usher Syndrome, Inherited Retinal Disease (IRD), Rod-Cone Dystrophy, Rod-Cone Disease, Retinal Degeneration, Cone-Rod Disease (C-RD), Cone-Rod Dystrophy
In brief
Study OpCT-001-101 is a Phase 1/2a first-in-human, multisite, 2-part interventional study to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001 in approximately 54 adults with primary photoreceptor (PR) disease. Phase 1 focuses on safety and features a dose-escalation design. Phase 2 is designed to gather additional safety data and assess the effect of OpCT-001 on measures of visual function, functional vision, and anatomic measures of engraftment in different clinical subgroups.
Key facts
- Study ID
- NCT06789445
- Run by
- BlueRock Therapeutics
- People needed
- 54
- Starts
- 2025-03-10
- Expected to finish
- 2030-10-01
- Last updated by the study team
- 2026-07-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Southern California /Children's Hospital of Los Angeles — Los Angeles, California, United States (enrolling)
- University of Miami, Bascom Palmer Eye Institute — Miami, Florida, United States (enrolling)
- Mid Atlantic Retina/ Wills Eye — Philadelphia, Pennsylvania, United States (enrolling)
- Retina Foundation of the Southwest — Dallas, Texas, United States (enrolling)
- University of Wisconsin — Madison, Wisconsin, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.